Synthesis of 4-[5-(methylthio)-1,3,4-oxadiazol-2-yl]-aniline (1)
1:15
Synthesis of Tert-butyl[18-({4-[5-(methylthio)-1,3,4-oxadiazol-2-yl]phenyl}amino)-15,18-dioxo-4,7,10-trioxa-14-azaoctadecyl] Carbamate (2)
3:00
Synthesis of Tert-butyl[18-({4-[5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl]phenyl}amino)-15,18-dioxo-4,7,10-trioxa-14-azaoctadecyl] Carbamate (3)
3:55
Synthesis of N1-(3-{2-[2-(3-aminopropoxy)ethoxy]-ethoxy}propyl)-N4-{4-[5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl] phenyl}Succinamide (PODS)
4:47
Synthesis of PODS-DOTA and Bioconjugation of PODS-DOTA to Trastuzumab
6:05
Results: Synthesis of PODS and PODS-DOTA and Conjugation to Trastuzumab
8:01
Conclusion
副本
This protocol describes the synthesis and application of PODS, a new reagent for the site-specific bioconjugation of proteins and peptides. This technology represents a marked improvement over traditional maleimide-thiol-based bioconjugations. The
登录或开始您的免费试用以访问此内容
In this protocol, we will describe the synthesis of PODS, a phenyoxadiazolyl methyl sulfone-based reagent for the site-selective attachment of cargos to the thiols of biomolecules, particularly antibodies. In addition, we will describe the synthesis and characterization of a PODS-bearing bifunctional chelator and its conjugation to a model antibody.